17 results on '"Jinen Song"'
Search Results
2. Protocol for identifying immune checkpoint on circulating tumor cells of human pancreatic ductal adenocarcinoma by single-cell RNA sequencing
- Author
-
Xiaowei Liu, Jinen Song, Xinyu Liu, Hao Zhang, Xueyan Wang, Yuanxi Li, Zhankun Yang, Jing Jing, Xuelei Ma, and Hubing Shi
- Subjects
Bioinformatics ,Sequence Analysis ,Cell Biology ,Cell Isolation ,Single Cell ,Flow Cytometry/Mass Cytometry ,Science (General) ,Q1-390 - Abstract
Summary: Circulating tumor cells (CTCs) are regarded as the “seeds” of tumor metastasis. Identifying immune checkpoints on CTCs is essential for establishing efficient immunotherapies to prevent tumor metastasis. Here, we present a protocol for isolating CTCs and obtaining single-cell suspensions from pancreatic ductal adenocarcinoma liver metastatic patients. We describe steps for biospecimen acquisition, CTC isolation, and tissue dissociation. We then detail procedures for performing single-cell RNA-seq, annotating cell types, and identifying immune checkpoints on CTCs.For complete details on the use and execution of this protocol, please refer to Liu et al. (2023).1 : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
- Published
- 2023
- Full Text
- View/download PDF
3. Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis
- Author
-
Xiaobo Zheng, Jinen Song, Chune Yu, Zongguang Zhou, Xiaowei Liu, Jing Yu, Guangchao Xu, Jiqiao Yang, Xiujing He, Xin Bai, Ya Luo, Yu Bao, Huifang Li, Lie Yang, Mingqing Xu, Nan Song, Xiaodong Su, Jie Xu, Xuelei Ma, and Hubing Shi
- Subjects
Medicine ,Biology (General) ,QH301-705.5 - Abstract
Abstract The adenoma-carcinoma sequence is a well-accepted roadmap for the development of sporadic colorectal cancer. However, cellular heterogeneity in aberrant epithelial cells limits our understanding of carcinogenesis in colorectal tissues. Here, we performed a single-cell RNA sequencing survey of 54,788 cells from patient-matched tissue samples, including blood, normal tissue, para-cancer, polyp, and colorectal cancer. At each stage of carcinogenesis, we characterized cell types, transcriptional signatures, and differentially expressed genes of distinct cell populations. The molecular signatures of epithelial cells at normal, benign, and malignant stages were defined at the single-cell scale. Adenoma and carcinoma precursor cell populations were identified and characterized followed by validation with large cohort biopsies. Protein tyrosine kinases (PTKs) BMX and HCK were identified as potential drivers of adenoma initiation. Specific BMX and HCK upregulations were observed in adenoma precursor cell populations from normal and adenoma biopsies. Overexpression of BMX and HCK significantly promoted colorectal epithelial cell proliferation. Importantly, in the organoid culture system, BMX and HCK upregulations resulted in the formation of multilayered polyp-like buds protruding towards the organoid lumen, mimicking the pathological polyp morphology often observed in colorectal cancer. Molecular mechanism analysis revealed that upregulation of BMX or HCK activated the JAK-STAT pathway. In conclusion, our work improved the current knowledge regarding colorectal epithelial evolution during carcinogenesis at the single-cell resolution. These findings may lead to improvements in colorectal cancer diagnosis and treatment.
- Published
- 2022
- Full Text
- View/download PDF
4. Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
- Author
-
Jing Yu, Xi Wu, Jinen Song, Yujie Zhao, Huifang Li, Min Luo, and Xiaowei Liu
- Subjects
melanoma ,MAPK-targeted therapy ,immune checkpoint blockade ,tumor immune microenvironment ,MHC-I antigen presentation ,drug resistance (DR) ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Immune checkpoint blockade and MAPK-targeted combined therapy is a promising regimen for advanced melanoma patients. However, the clinical benefit from this combo regimen remains limited, especially in patients who acquired resistance to MAPK-targeted therapy. Here, we systematically characterized the immune landscape during MAPK-targeted therapy in patients and mouse melanoma models. We observed that both the abundance of tumor-infiltrated T cells and the expression of immune-related genes were upregulated in the drug-responsive period, but downregulated in the resistance period, implying that acquired drug resistance dampens the antitumor immune response. Further transcriptomic dissection indicated that loss of MHC-I antigen presentation on tumor cells plays a critical role in the reduction of T cell infiltration during drug resistance. Survival analysis demonstrates that loss of antigen presentation and reduction of T-cell infiltration during acquired drug resistance are associated with poorer clinical response and prognosis of anti-PD-1 therapy in melanoma patients. In addition, we identified that alterations in the MAPK inhibitor resistance-related oncogenic signaling pathway closely correlated with deficiency of MHC-I antigen presentation, including activation of the PI3K-mTOR, MAPK, and Wnt pathways. In conclusion, our research illuminates that decreased infiltration of T cells is associated with acquired drug resistance during MAPK-targeted therapy, which may underlie the cross-resistance to immune checkpoint blockade.
- Published
- 2022
- Full Text
- View/download PDF
5. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
- Author
-
Xin Bai, Xueyan Wang, Guozhen Ma, Jinen Song, Xiaowei Liu, Xi Wu, Yujie Zhao, Xu Liu, Zhihui Liu, Wei Zhang, Xin Zhao, Zirui Zheng, Jing Jing, and Hubing Shi
- Subjects
immune checkpoint blockade ,immune-related adverse events ,mTOR inhibitor ,effector T-cells ,melanoma ,Immunologic diseases. Allergy ,RC581-607 - Abstract
During the past decades, immunotherapy, especially the antibody-mediated immune checkpoint blockade (ICB) has shown durable tumor inhibition and changed the paradigm of cancer treatment. However, a growing body of evidence suggests that ICB treatment induces severe immune-related adverse events (irAEs), and the side effect even leads to the discontinuation of lifesaving treatment. Here, we found that ICB treatment induces colitis in melanoma patients and promotes the infiltration of CD8+ effector T cells into colitic lesions. Further transcriptomic dissection indicated the PI3K-AKT-mTOR pathway was highly activated in CD8+ effector T cells of colitic lesions. Moreover, we developed a mouse melanoma model to recapitulate the gastrointestinal toxicity of anti-PD-1 treatment in clinical settings. Anti-PD-1 treatment significantly contributed to the infiltration of CD8+ T cells, and correspondingly induced severe enteritis. Immunohistochemistry experiments showed that the PI3K-AKT-mTOR pathway of T cells was activated by anti-PD-1 treatment. Blockade of the pathway with mTOR inhibitor sirolimus not only inhibits tumor growth but also suppresses the T cell infiltration in colitic lesions. More importantly, combination with sirolimus and anti-PD-1 synergistically inhibits tumor growth via inducing the immunogenic cell death of tumor cells in vivo. In summary, our research demonstrated the principle of mTOR inhibitor and anti-PD-1 combinatorial therapeutic regimen, which provided a novel therapeutic strategy for irAEs in clinics.
- Published
- 2021
- Full Text
- View/download PDF
6. Differential diagnosis of pancreatic serous cystadenoma and mucinous cystadenoma: utility of textural features in combination with morphological characteristics
- Author
-
Jing Yang, Xinli Guo, Hao Zhang, Weiwei Zhang, Jinen Song, Hui Xu, and Xuelei Ma
- Subjects
Pancreas ,Serous cystadenoma ,Mucinous cystadenoma ,Diagnosis ,Multidetector computed tomography ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Texture analysis of medical images has been reported to be a reliable method for differential diagnosis of neoplasms. This study was to investigate the performance of textural features and the combined performance of textural features and morphological characteristics in the differential diagnosis of pancreatic serous and mucinous cystadenomas. Methods We retrospectively reviewed 59 patients with pancreatic serous cystadenoma and 32 patients with pancreatic mucinous cystadenoma at our hospital. A three-dimensional region of interest (ROI) around the margin of the lesion was drawn manually in the CT images of each patient, and textural parameters were retrieved from the ROI. Textural features were extracted using the LifeX software. The least absolute shrinkage and selection operator (LASSO) method was applied to select the textural features. The differential diagnostic capabilities of morphological features, textural features, and their combination were evaluated using receiver operating characteristic (ROC) analysis, and the area under the receiver operating characteristic curve (AUC) was used as the main indicator. The diagnostic accuracy based on the AUC value is defined as follows: 0.9–1.0, excellent; 0.8–0.9, good; 0.7–0.8, moderate; 0.6–0.7, fair; 0.5–0.6, poor. Results In the differential diagnosis of pancreatic serous and mucinous cystadenomas, the combination of morphological characteristics and textural features (AUC 0.893, 95% CI 0.816–0.970) is better than morphological characteristics (AUC 0.783, 95% CI 0.665–0.900) or textural features (AUC 0.777, 95% CI 0.673–0.880) alone. Conclusions In conclusion, our preliminary results highlighted the potential of CT texture analysis in discriminating pancreatic serous cystadenoma from mucinous cystadenoma. Furthermore, the combination of morphological characteristics and textural features can significantly improve the diagnostic performance, which may provide a reliable method for selecting patients with surgical intervention indications in consideration of the different treatment principles of the two diseases.
- Published
- 2019
- Full Text
- View/download PDF
7. Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells
- Author
-
Fei Mo, Yinan Xiao, Hao Zeng, Dian Fan, Jinen Song, Xiaobei Liu, Meng Luo, and Xuelei Ma
- Subjects
curcumin ,small cell lung cancer ,apoptosis ,miR-548ah-5p ,high-throughput sequencing ,Biology (General) ,QH301-705.5 - Abstract
BackgroundCurcumin, one of the promising candidates for supplementary therapy in cancer treatment, has been demonstrated by numerous preclinical and clinical evidence to be beneficial in treating various cancers. Apart from the critical role in a deluge of pathological processes, some mRNAs, in particular, microRNAs (miRNAs), are also involved in the anti-tumor activity. Therefore, our research focused on the possible effects of curcumin on small cell lung cancer (SCLC) cells and drew a comprehensive transcriptomes profile by high throughput sequencing to understand the molecular mechanism of curcumin as an anti-tumor agent.MethodsFirst, we calculated the apoptosis rate of H446 cells (a human SCLC cell line) cultured with curcumin. The high output sequencing uncovered the altered expression profile of genes and miRNAs. KEGG analysis selected the potential signal pathway associated with the antiproliferative property of curcumin. Finally, miRNAs significantly changed, as well as the regulatory roles of those miRNAs in cell apoptosis were determined.ResultThe apoptosis rate of H446 cells increased under the elevated concentration of curcumin treatment. And cell cycle-related genes downregulated in the curcumin-treated cells. Besides, miRNA-548ah-5p of a high level acted as a negative role in the anticarcinogenic activity of curcumin.ConclusionOur findings not only enriched the understanding of anti-tumor activity initiated by curcumin through figuring out the downregulated cell cycle-related pathways but also shed light on its novel therapeutic application.
- Published
- 2021
- Full Text
- View/download PDF
8. Intraoperative application of inactivated Pseudomonas aeruginosa in patients undergoing lateral neck dissection for metastatic thyroid cancer: A randomized, parallel group, placebo-controlled trial
- Author
-
Genpeng, Li, Jinen, Song, Tao, Wei, Zhihui, Li, Rixiang, Gong, Jianyong, Lei, and Jingqiang, Zhu
- Published
- 2020
- Full Text
- View/download PDF
9. Dexamethasone for Postoperative Nausea and Vomiting in Papillary Thyroid Carcinoma Patients: A Randomized Clinical Trial
- Author
-
Wenjie Chen, Genpeng Li, Ke Jiang, Jinen Song, Runzi Du, Hui Yang, Juxiang Gou, Zhihui Li, Jingqiang Zhu, and Jianyong Lei
- Subjects
Pain, Postoperative ,Double-Blind Method ,Thyroid Cancer, Papillary ,Postoperative Nausea and Vomiting ,Humans ,Surgery ,Thyroid Neoplasms ,Dexamethasone - Abstract
Postoperative nausea and vomiting (PONV) frequently occur after thyroidectomy. Previous studies have investigated the effects of preoperative dexamethasone for alleviating PONV in various cancers, but studies focused on papillary thyroid carcinoma (PTC) were limited. This study aimed to determine the efficacy of a single preoperative dose of dexamethasone to prevent PONV in patients with PTC.This single-center, parallel-group, double-blind, placebo-controlled clinical trial was conducted on patients with PTC in West China Hospital. Patients were randomized 1:1 into Group Dex (preoperative 8-mg dexamethasone) or Group Control (0.9% NaCl as control). The primary outcome was the incidence and severity of PONV. The secondary outcomes included postoperative pain, vocal dysfunction, and adverse events.Six hundred participants were recruited and randomized. The total incidence of PONV was 33.3% (200 of 600 patients; 95% CI, 29.6-37.1). In the intention-to-treat analysis, PONV occurred in 81 of 300 patients (27.0%; 95% CI, 21.9-32.1) in Group Dex and in 119 of 300 patients (39.7%; 95% CI, 34.1-45.2) in Group Control (p = 0.001), and the absolute risk reduction was 12.7% (95% CI, 5.1-20.0). Patients in Group Dex reported fewer antiemetic requirements than those in Group Control (p = 0.004). Multivariate analysis indicated that dexamethasone administration (OR = 0.546; 95% CI, 0.383-0.777; p = 0.001) was associated with a reduced rate of PONV. Dexamethasone treatment also contributed to alleviating postoperative pain and improving subjective vocal dysfunction, with no increase in adverse events.A single dose of dexamethasone is effective and safe for preventing PONV in PTC patients.
- Published
- 2022
10. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance
- Author
-
Xiaowei Liu, Jinen Song, Hao Zhang, Xinyu Liu, Fengli Zuo, Yunuo Zhao, Yujie Zhao, Xiaomeng Yin, Xinyu Guo, Xi Wu, Hu Zhang, Jie Xu, Jianping Hu, Jing Jing, Xuelei Ma, and Hubing Shi
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
11. Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis
- Author
-
Xiaobo Zheng, Jinen Song, Chune Yu, Zongguang Zhou, Xiaowei Liu, Jing Yu, Guangchao Xu, Jiqiao Yang, Xiujing He, Xin Bai, Ya Luo, Yu Bao, Huifang Li, Lie Yang, Mingqing Xu, Nan Song, Xiaodong Su, Jie Xu, Xuelei Ma, and Hubing Shi
- Subjects
Adenoma ,Cancer Research ,STAT Transcription Factors ,Carcinogenesis ,Genetics ,Humans ,Colorectal Neoplasms ,Transcriptome ,Janus Kinases ,Signal Transduction - Abstract
The adenoma-carcinoma sequence is a well-accepted roadmap for the development of sporadic colorectal cancer. However, cellular heterogeneity in aberrant epithelial cells limits our understanding of carcinogenesis in colorectal tissues. Here, we performed a single-cell RNA sequencing survey of 54,788 cells from patient-matched tissue samples, including blood, normal tissue, para-cancer, polyp, and colorectal cancer. At each stage of carcinogenesis, we characterized cell types, transcriptional signatures, and differentially expressed genes of distinct cell populations. The molecular signatures of epithelial cells at normal, benign, and malignant stages were defined at the single-cell scale. Adenoma and carcinoma precursor cell populations were identified and characterized followed by validation with large cohort biopsies. Protein tyrosine kinases (PTKs) BMX and HCK were identified as potential drivers of adenoma initiation. Specific BMX and HCK upregulations were observed in adenoma precursor cell populations from normal and adenoma biopsies. Overexpression of BMX and HCK significantly promoted colorectal epithelial cell proliferation. Importantly, in the organoid culture system, BMX and HCK upregulations resulted in the formation of multilayered polyp-like buds protruding towards the organoid lumen, mimicking the pathological polyp morphology often observed in colorectal cancer. Molecular mechanism analysis revealed that upregulation of BMX or HCK activated the JAK-STAT pathway. In conclusion, our work improved the current knowledge regarding colorectal epithelial evolution during carcinogenesis at the single-cell resolution. These findings may lead to improvements in colorectal cancer diagnosis and treatment.
- Published
- 2021
12. Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade
- Author
-
Xi Wu, Ya Luo, Yanlin Feng, Xin Bai, Yan Fu, Hubing Shi, Ying Shi, Yu Bao, Changyang Gong, Jie Xu, Jianping Hu, Li Chai, Bo Chen, Rongjie Zhang, Yan Wang, Xiaowei Liu, Huifang Li, Jinen Song, Haiyuan Zhang, Yongzhang Luo, and Jiqiao Yang
- Subjects
Photothermal Therapy ,medicine.medical_treatment ,Pharmaceutical Science ,02 engineering and technology ,Targeted therapy ,03 medical and health sciences ,Immune system ,Cell Line, Tumor ,Tumor Microenvironment ,Medicine ,Humans ,Immune Checkpoint Inhibitors ,030304 developmental biology ,0303 health sciences ,Tumor microenvironment ,business.industry ,Melanoma ,021001 nanoscience & nanotechnology ,medicine.disease ,Immune checkpoint ,Blockade ,Regimen ,Cancer research ,Immunogenic cell death ,Gold ,0210 nano-technology ,business - Abstract
The combination of MAPK-targeted therapy and immune checkpoint blockade is one of the most promising regimens for patients with advanced melanoma. However, the synergistic efficacy of the combo regimen is still controversial in clinical trials. Here, we report that MAPK inhibition induced T-cell suppression within tumor microenvironment is mediated by attenuation of HSP27/HSP70 and deficiency of neoantigen presentation. To address this problem, we designed a photothermal-responsive on-demand controlled drug release gold nano-system to carry BRAF inhibitor. The nano-system can be specifically delivered into tumor cells rather than T-cells, and effectively transformed the optical energy into heat energy upon laser irradiation. Combination of photothermal and targeted therapy significantly promoted immunogenic cell death and T-cell infiltration. On top of this regimen, systematically administration of PD-1 antibody not only suppressed local-treated tumor but also inhibited abscopal tumor by enhancing generalized immune-related antitumor response. More importantly, the triple-combo regimen could efficiently convert immune "cold" tumors into "hot" ones. In conclusion, our research proves the advantage of photothermal-targeted-immune triple combinatorial regimen in treating tumors which are clinical unresectable multifocal and lack of T-cell infiltration.
- Published
- 2020
13. Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy
- Author
-
Hubing Shi, Chune Yu, Xiaobo Zheng, Jinen Song, Yu Bao, Jiang Lan, Guangchao Xu, Jingyi Jessica Li, Dan Luo, Jianping Hu, and Min Zhang
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Integrin ,Resistance ,PI3K ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Clinical Research ,Protein kinase B ,Melanoma ,PI3K/AKT/mTOR pathway ,Cancer ,YAP1 ,biology ,Chemistry ,Kinase ,Research ,Wnt signaling pathway ,Integrin-Src-YAP1 axis ,MAPK ,PI3K/mTOR ,030104 developmental biology ,5.1 Pharmaceuticals ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,mTOR ,Development of treatments and therapeutic interventions ,Proto-oncogene tyrosine-protein kinase Src - Abstract
Activation of PI3K/AKT pathway is one of the most recurrent resistant mechanisms for BRAF-targeted therapy, and the combination of MAPK and PI3K/AKT inhibitors becomes one of the most promising regimens for BRAF-targeted relapsed melanoma patients. Although the potent drug efficacy was observed in preclinical experiments and early clinical trials, the dual-drug resistance is inevitable observed. In this study, we systematically explored the mechanisms of dual-drug resistance to MAPKi and PI3K/mTORi in melanoma. With transcriptomic dissection of dual-drug resistant models, we identified that the drug tolerance was mediated by ECM-integrins α3β1 and α11β1 signaling. Upon binding ECM, the integrins activated downstream kinase Src rather than FAK, WNT, or TGFβ. Knockdown of integrins α3, α11, and β1 significantly inhibited the proliferation of dual-drug resistant sublines while with trivial effects on parental cells. Although Src inhibition suppressed the phosphorylation of AKT, c-JUN, and p38, none of inhibitors targeting these kinases reversed the dual-drug resistance in model cells. Notably, Src inhibitor promoted the phosphorylations of LATS1 and YAP1, subsequently, re-localized YAP1 from nucleus to cytosol facilitating further degradation. Both small molecule inhibitors and shRNAs targeting YAP1 or Src overcame the MAPKi and PI3K/mTORi dual-drug resistance. In conclusion, our data not only illuminated an integrin-Src-YAP1 pathway mediated MAPKi and PI3K/mTORi dual-drug resistant mechanism but also provided a potential combinatorial regimen for the drug-relapsed melanoma patients.
- Published
- 2020
14. Response to letter from Panda et al regarding “Intraoperative application of inactivated Pseudomonas aeruginosa in patients undergoing lateral neck dissection for metastatic thyroid cancer: A randomized, parallel group, placebo-controlled trial”
- Author
-
Genpeng, Li, primary, Tao, Wei, additional, Zhihui, Li, additional, Rixiang, Gong, additional, Jianyong, Lei, additional, Jingqiang, Zhu, additional, and Jinen, Song, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Differential Diagnosis of Pancreatic Serous Cystadenomas and Mucinous Cystadenomas: Utility of Texture Analysis in Combination with Morphological Characteristics
- Author
-
Jing Yang, Xinli Guo, Weiwei Zhang, Jinen Song, Xuelei Ma, and Hui Xu
- Abstract
Background Texture analysis of medical images has been reported to be a reliable technique for differential diagnosis of neoplasms. This study was to investigate the performance of textural features and the combined performance of textural features and morphological characteristics in the differential diagnosis of pancreatic serous and mucinous cystadenomas. Methods We retrospectively reviewed 59 patients with pancreatic serous cystadenoma and 32 patients with pancreatic mucinous cystadenoma at our hospital. Textural features were extracted using the LifeX software, and the least absolute shrinkage and selection operator (LASSO) method was applied to select the textural features. The differential diagnostic abilities of morphological features, textural features, and their combination were evaluated using receiver operating characteristic (ROC) analysis, with the area under the receiver operating characteristic curve (AUC) as the main indicator. Results The combination of morphological characteristics and textural features showed a higher AUC (0.893, 95% CI 0.816-0.970) than use of morphological characteristics (0.783, 95% CI 0.665-0.900) or textural features (0.777, 95% CI 0.673-0.880) alone. Conclusions In conclusion, our preliminary results highlighted the potential of CT texture analysis to discriminate pancreatic serous cystadenomas from mucinous cystadenomas. Furthermore, the combination of morphological and textural features can significantly improve the diagnostic performance, which may provide a reliable method to select patients with indication of surgical intervention in consideration of the different treatment principles of the two diseases.
- Published
- 2019
- Full Text
- View/download PDF
16. MOESM1 of Differential diagnosis of pancreatic serous cystadenoma and mucinous cystadenoma: utility of textural features in combination with morphological characteristics
- Author
-
Yang, Jing, Xinli Guo, Zhang, Hao, Weiwei Zhang, Jinen Song, Xu, Hui, and Xuelei Ma
- Abstract
Additional file 1: Figure S1. Flowchart of the patient selection. Figure S2. Transverse CT scan obtained in a patient with mucinous cystadenoma. Image shows a round cystic lesion (white arrow) in the tail of the pancreas surrounded by an enhancing wall. Note the septum (black arrow). Figure S3. Receiver Operating Characteristic (ROC) analysis based on the observations of the readers. The area under the receiver operating characteristic curve was 0.642 (95% CI 0.522–0.761).
- Published
- 2019
- Full Text
- View/download PDF
17. MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression
- Author
-
Ya Luo, Hubing Shi, Bowen Ke, Xiaowei Liu, Haiyuan Zhang, Yanlin Feng, Jinen Song, Haoyu Ye, Jiqiao Yang, Yang Chen, Chune Yu, Jie Xu, Yu Bao, Bo Chen, Jianping Hu, Huan Meng, Guangchao Xu, and Yanna Li
- Subjects
Drug ,MAPK/ERK pathway ,media_common.quotation_subject ,Melanoma ,T cell ,medicine.medical_treatment ,Biology ,Condensed Matter Physics ,medicine.disease ,Electronic, Optical and Magnetic Materials ,Targeted therapy ,Biomaterials ,medicine.anatomical_structure ,Electrochemistry ,medicine ,Cancer research ,Pd 1 blockade ,Nanocarriers ,media_common - Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.